Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface - PubMed (original) (raw)
Review
Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface
C T Esmon. FASEB J. 1995 Jul.
Abstract
The protein C anticoagulant system generates an "on demand" physiologic anticoagulant response. The pathway is initiated when thrombin binds to the endothelial cell thrombin binding protein, thrombomodulin. The complex exhibits dramatically altered macromolecular specificity. It rapidly cleaves the protein C zymogen to form the anticoagulant, activated protein C. Complex formation between thrombin and thrombomodulin also prevents thrombin, the enzyme responsible for clot formation and a potent platelet activator, from being able to clot fibrinogen or to activate platelets. Structural, kinetic, and competition studies suggest that thrombomodulin blocks these clotting reactions by masking the binding sites for fibrinogen and the platelet thrombin receptor. Stimulation of protein C activation appears to occur through conformational changes in the extended binding pocket of thrombin. This prevents repulsive interactions with protein C that exist when the free enzyme attempts to dock with this substrate. In addition to protein-protein interactions, thrombomodulin has a covalently associated chondroitin sulfate moiety. Chondroitin sulfate binds to a basic surface on thrombin that is also involved in heparin interaction. The chondroitin sulfate enhances the affinity of thrombin for thrombomodulin approximately 10- to 20-fold, making thrombomodulin a more potent inhibitor of coagulation, altering thrombin's conformation and specificity, and accelerating thrombin inhibition by the serpin, antithrombin. These properties make thrombomodulin a molecular switch ideally suited to trigger an anticoagulant response when too much thrombin is generated. The importance of the system is documented by the clinical observation that patients deficient in protein C often die of massive thrombotic complications that can be reversed or prevented by infusion of protein C.
Similar articles
- Energetics of thrombin-thrombomodulin interaction.
Vindigni A, White CE, Komives EA, Di Cera E. Vindigni A, et al. Biochemistry. 1997 Jun 3;36(22):6674-81. doi: 10.1021/bi962766a. Biochemistry. 1997. PMID: 9184147 - Structure-function relationships of the thrombin-thrombomodulin interaction.
Sadler JE, Lentz SR, Sheehan JP, Tsiang M, Wu Q. Sadler JE, et al. Haemostasis. 1993 Mar;23 Suppl 1:183-93. doi: 10.1159/000216927. Haemostasis. 1993. PMID: 8388351 Review. - Occupancy of anion binding exosite 2 on thrombin determines Ca2+ dependence of protein C activation.
Liu LW, Rezaie AR, Carson CW, Esmon NL, Esmon CT. Liu LW, et al. J Biol Chem. 1994 Apr 22;269(16):11807-12. J Biol Chem. 1994. PMID: 8163479 - Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex.
Fuentes-Prior P, Iwanaga Y, Huber R, Pagila R, Rumennik G, Seto M, Morser J, Light DR, Bode W. Fuentes-Prior P, et al. Nature. 2000 Mar 30;404(6777):518-25. doi: 10.1038/35006683. Nature. 2000. PMID: 10761923 - Molecular events that control the protein C anticoagulant pathway.
Esmon CT. Esmon CT. Thromb Haemost. 1993 Jul 1;70(1):29-35. Thromb Haemost. 1993. PMID: 8236111 Review.
Cited by
- Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor.
Richardson JL, Kröger B, Hoeffken W, Sadler JE, Pereira P, Huber R, Bode W, Fuentes-Prior P. Richardson JL, et al. EMBO J. 2000 Nov 1;19(21):5650-60. doi: 10.1093/emboj/19.21.5650. EMBO J. 2000. PMID: 11060016 Free PMC article. - Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder.
Santoni M, Catanzariti F, Minardi D, Burattini L, Nabissi M, Muzzonigro G, Cascinu S, Santoni G. Santoni M, et al. Adv Urol. 2012;2012:397412. doi: 10.1155/2012/397412. Epub 2012 Jul 2. Adv Urol. 2012. PMID: 22811704 Free PMC article. - Statins as a novel therapeutic strategy in acute lung injury.
Singla S, Jacobson JR. Singla S, et al. Pulm Circ. 2012 Oct;2(4):397-406. doi: 10.4103/2045-8932.105028. Pulm Circ. 2012. PMID: 23372924 Free PMC article. - Elevation of the soluble thrombomodulin levels is associated with inflammation after percutaneous coronary interventions.
Chao TH, Li YH, Tsai WC, Chen JH, Liu PY, Tsai LM. Chao TH, et al. Clin Cardiol. 2004 Jul;27(7):407-10. doi: 10.1002/clc.4960270708. Clin Cardiol. 2004. PMID: 15298041 Free PMC article. - New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).
Macias WL, Yan SB, Williams MD, Um SL, Sandusky GE, Ballard DW, Planquois JM. Macias WL, et al. Crit Care. 2005;9 Suppl 4(Suppl 4):S38-45. doi: 10.1186/cc3747. Epub 2005 Aug 25. Crit Care. 2005. PMID: 16168074 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources